Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment.

Heart failure (HF) is classified based upon the left ventricular ejection fraction (LVEF). Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder with increasing prevalence in the elderly that remains incompletely understood and inadequately treated as no therapy has shown favorable effects. In this review, we summarize the current theories regarding HFpEF pathogenesis, propose a phenotype-based classification of HFpEF, discuss prevention strategies, explain why clinical trials on HFpEF treatment have failed, and make suggestions for the future.

[1]  Shannon M. Dunlay,et al.  Epidemiology of heart failure with preserved ejection fraction , 2017, Nature Reviews Cardiology.

[2]  Sanjiv J. Shah,et al.  INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. , 2017, Circulation. Heart failure.

[3]  V. Melenovský,et al.  Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. , 2016, Circulation research.

[4]  V. Melenovský,et al.  Differential Hemodynamic Effects of Exercise and Volume Expansion in People With and Without Heart Failure , 2015, Circulation. Heart failure.

[5]  R. Nishimura,et al.  Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction , 2010, Circulation. Heart failure.

[6]  L. Lund,et al.  Survival After Coronary Artery Bypass Grafting in Patients With Preoperative Heart Failure and Preserved vs Reduced Ejection Fraction. , 2016, JAMA cardiology.

[7]  B. Maron,et al.  The Invasive Cardiopulmonary Exercise Test , 2013, Circulation.

[8]  P. Ennezat,et al.  Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction , 2016, Journal of the American Heart Association.

[9]  Matthew G. Johnson,et al.  Central obesity: association with left ventricular dysfunction and mortality in the community. , 2008, American heart journal.

[10]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[11]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[12]  A. Schechter,et al.  Inorganic nitrate: a major player in the cardiovascular health benefits of vegetables? , 2012, Nutrition reviews.

[13]  F. Larsen,et al.  Roles of dietary inorganic nitrate in cardiovascular health and disease. , 2011, Cardiovascular research.

[14]  N. Houstis,et al.  Why Don't We Have Proven Treatments for HFpEF? , 2017, Circulation research.

[15]  R. Wachter,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. , 2016, European heart journal.

[16]  M. Vaduganathan,et al.  Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review , 2016, European journal of heart failure.

[17]  V. Roger,et al.  Multimorbidity in heart failure: a community perspective. , 2015, The American journal of medicine.

[18]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[19]  D. Kitzman,et al.  Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions , 2017, American Journal of Cardiovascular Drugs.

[20]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[21]  S. Farris,et al.  Heart failure with preserved ejection fraction and skeletal muscle physiology , 2017, Heart Failure Reviews.

[22]  Adelaide M. Arruda-Olson,et al.  Sleep Apnea and Cardiovascular Disease , 2003, Herz.

[23]  B. Levine,et al.  Impact of lifelong exercise "dose" on left ventricular compliance and distensibility. , 2014, Journal of the American College of Cardiology.

[24]  C. Fonseca,et al.  Prevalence of chronic heart failure in Southwestern Europe: the EPICA study , 2002, European journal of heart failure.

[25]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[26]  K. Anstrom,et al.  Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial , 2017, European journal of heart failure.

[27]  V. Melenovský,et al.  Implications of coronary artery disease in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[28]  Akshay S. Desai,et al.  Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. , 2017, The New England journal of medicine.

[29]  R. McKelvie,et al.  Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and AnginaCLINICAL PERSPECTIVE , 2015 .

[30]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[31]  M. Redfield.  Heart Failure with Preserved Ejection Fraction. , 2016, The New England journal of medicine.

[32]  Mark T. Gladwin,et al.  The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics , 2008, Nature Reviews Drug Discovery.

[33]  M. Gladwin,et al.  Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation , 2003, Nature Medicine.

[34]  W. Paulus,et al.  Pathophysiological rationale and diagnostic targets for diastolic stress testing , 2015, Heart.

[35]  C. Ayers,et al.  Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. , 2017, Journal of the American College of Cardiology.

[36]  Natalia C. Berry,et al.  Protocol for Exercise Hemodynamic Assessment: Performing an Invasive Cardiopulmonary Exercise Test in Clinical Practice , 2015, Pulmonary circulation.

[37]  E. Lakatta,et al.  Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction: The Health ABC Study (Health, Aging, and Body Composition) , 2017, Hypertension.

[38]  M. Hezel,et al.  Nitrate-Nitrite-Nitric Oxide Pathway: Implications for Anesthesiology and Intensive Care , 2010, Anesthesiology.

[39]  V. Melenovský,et al.  The Role of Diastolic Stress Testing in the Evaluation for HFpEF : A Simultaneous Invasive-Echocardiographic Study , 2016 .

[40]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[41]  J. Higaki,et al.  Association of worsening arterial stiffness with incident heart failure in asymptomatic patients with cardiovascular risk factors , 2017, Hypertension Research.

[42]  F. Neumann,et al.  Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. , 2014, European heart journal.

[43]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[44]  B. Borlaug.  Is HFpEF One Disease or Many? , 2016, Journal of the American College of Cardiology.

[45]  G. Filippatos,et al.  Reframing the association and significance of co‐morbidities in heart failure , 2016, European journal of heart failure.

[46]  William T. Abraham,et al.  Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[47]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[48]  Wolfgang A. Linke,et al.  Heart failure with preserved ejection fraction , 2014, Pflügers Archiv - European Journal of Physiology.

[49]  N. Bryan,et al.  Nitrite and nitrate: cardiovascular risk–benefit and metabolic effect , 2011, Current opinion in lipidology.

[50]  Sanjiv J. Shah,et al.  Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone , 2015, Circulation.

[51]  V. Melenovský,et al.  Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. , 2017, Journal of the American College of Cardiology.

[52]  D. Vinereanu,et al.  The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction: add global longitudinal strain to the list , 2017, European journal of heart failure.

[53]  Ruoxiang Jiang,et al.  A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. , 2015, JAMA internal medicine.

[54]  Sanjiv J. Shah,et al.  Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. , 2017, Circulation.

[55]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[56]  M. Khan,et al.  Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis , 2017, ESC heart failure.

[57]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[58]  E. Lakatta,et al.  Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. , 2015, Hypertension.

[59]  Sanjiv J. Shah,et al.  Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT , 2017, Current Heart Failure Reports.

[60]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[61]  Sanjiv J. Shah,et al.  A Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure with Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2, Randomized, Sham-Controlled Trial , 2017 .

[62]  Michael A. Burke,et al.  Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[63]  L. Lerman,et al.  Percutaneous Pericardial ResectionCLINICAL PERSPECTIVE , 2017 .

[64]  V. Roger,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.

[65]  M. O'Rourke,et al.  Mechanical factors in arterial aging: a clinical perspective. , 2007, Journal of the American College of Cardiology.

[66]  R. Townsend,et al.  Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[67]  Gabriel A. Koepp,et al.  Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. , 2015, The New England journal of medicine.

[68]  D. Burkhoff,et al.  A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial , 2016, The Lancet.

[69]  Luigi Tavazzi,et al.  Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey , 2014, European journal of heart failure.

[70]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[71]  S. Bangalore,et al.  The Transition From Hypertension to Heart Failure: Contemporary Update. , 2017, JACC. Heart failure.

[72]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[73]  D. Levy,et al.  Relation of Central Arterial Stiffness to Incident Heart Failure in the Community , 2015, Journal of the American Heart Association.

[74]  Akshay S. Desai,et al.  After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. , 2016, European heart journal.